For patients with multiple myeloma, the use of novel agents in first-line triplet and quadruplet induction regimens -- with or without high-dose therapy and autologous stem cell transplant (ASCT) -- ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult ...

The findings contradict previous research suggesting high-risk patients with multiple myeloma were more likely to have a ...

The FDA approved Lynozyfic for relapsed multiple myeloma, but serious risks require restricted use under a special safety program.

Number one is, given the high degree of efficacy that the CAR T cells have, there's a great interest in knowing should we really be waiting for giving these CAR T cells to patients with relapse and ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

During a live event, Jeffrey V. Matous, MD, discussed flexible dosing and the need to expand use in community practices for ...

The future of multiple myeloma treatment is personalised, but collaboration is essential to deliver it. Learn about the latest advancements and how working together can improve outcomes for patients.

Myeloma articles from across Nature Portfolio Myeloma, or multiple myeloma, is a cancer affecting a particular type of blood cells, called plasma cells. Myeloma is most common in people over 60 ...

GSK continues to build the case for its multiple myeloma therapy Blenrep, which was pulled from the US market last year, with another positive phase 3 trial. The BCMA-targeted antibody-drug ...

A team of researchers led by NYU Tandon School of Engineering's Weiqiang Chen has developed a miniature device that could ...